Welcome to our dedicated page for Vicarious Surgical news (Ticker: RBOT), a resource for investors and traders seeking the latest updates and insights on Vicarious Surgical stock.
News for Vicarious Surgical Inc. (RBOT) centers on its progress in developing the Vicarious Surgical Robotic System and on key corporate and financing events. The company describes itself as a next-generation surgical robotics and medical device developer focused on minimally invasive surgery, with a system designed for abdominal access and 3D visualization through a single port.
Recent press releases highlight development milestones such as an in-vivo porcine lab in which surgeons used the company’s pre-DV system to complete key elements of a ventral hernia repair and evaluate subsystems including instrument articulation, energy delivery instruments and visualization. These updates provide insight into how the system performs in realistic surgical environments and how data from such labs inform design refinement, verification planning and system optimization.
Investors and observers will also find news about Vicarious Surgical’s operating model and cost structure. The company has issued cash burn guidance, discussed an operational reset, and announced reductions in headcount and external consulting spend, alongside increased use of strategic outsourcing and a strategic software execution partnership with a global digital engineering firm. These items describe how Vicarious Surgical is seeking to improve execution, increase development predictability and manage operating expenses while advancing toward system design milestones.
Additional news coverage includes quarterly financial results, registered direct offerings and private placements, at-the-market offering arrangements, board and committee changes, and participation in healthcare investment conferences. Together, these updates give a view into both the technical evolution of the Vicarious Surgical System and the company’s financing, governance and investor relations activities. Readers interested in RBOT can use this page to follow ongoing disclosures about development progress, financial guidance, capital raises and corporate governance developments.
Vicarious Surgical (NYSE:RBOT) announced the successful use of its Beta 2 prototype for cadaveric ventral hernia repairs by renowned surgeon Igor Belyansky. This milestone, showcasing advanced robotic surgical capabilities, is set to be highlighted on December 6, 2022, during Vicarious Surgical's Beta 2 Demonstration Day. The prototype aims to improve surgical efficiency and patient outcomes through minimally invasive techniques using a single-port approach. The collaboration with Belyansky underscores the company's commitment to innovation in robotic surgery.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) will participate in two upcoming investor conferences. The company, specializing in next-generation robotics to enhance surgical procedures, will host a virtual fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on November 29 at 3:05 p.m. ET, followed by another chat at the 34th Annual Piper Sandler Healthcare Conference on November 30 at 1:00 p.m. ET. Interested investors can access the presentations live or archived via the company's website.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) announces that its robotic system has been included in TIME's Best Inventions of 2022, recognized for its innovative design. The system utilizes one camera and two multi-jointed arms for minimally invasive surgeries, demonstrating a full replication of the surgeon's movements. The company completed its Beta 2 system design earlier this year and plans to showcase it on December 6, 2022. The technology has received FDA Breakthrough Device Designation, aiming to enhance surgical efficiency while reducing healthcare costs.
Vicarious Surgical (NYSE: RBOT, RBOT WS) announced its financial results for Q3 2022, reporting a significant increase in operating expenses to $22.2 million, up 159% from $8.6 million the previous year. R&D expenses rose to $12.1 million, while adjusted net loss was $21.7 million, or $0.18 per share, compared to a loss of $8.6 million, or $0.09 per share, in Q3 2021. The GAAP net loss was $24.7 million, down from $45.1 million year-over-year. The company ended the quarter with $126.8 million in cash and equivalents, maintaining a cash burn rate of $14.5 million.
Vicarious Surgical Inc. has signed a collaborative Memorandum of Understanding with Pittsburgh CREATES, enhancing its development of robotic surgical solutions. The partnership aims to leverage academic and clinical resources from the University of Pittsburgh and UPMC to improve surgical procedures' efficiency, outcomes, and cost-effectiveness.
This collaboration extends Vicarious Surgical's existing partnerships, providing access to a network of clinical and operational robotic experts.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) plans to release its third quarter 2022 financial results on November 7, 2022, after market close. A conference call will follow at 4:30 p.m. Eastern Time. This company focuses on enhancing surgical procedures through innovative robotics aimed at improving efficiency and reducing healthcare costs. Founded in 2014, Vicarious Surgical is supported by notable investors including Bill Gates and Khosla Ventures. Investors can access the call by dialing +1 (646) 904 5544 (domestic) or +1 (929) 526 1599 (international).
Vicarious Surgical Inc. announced the resignation of board members Dror Berman and Samir Kaul effective October 18, 2022. The company appointed Beverly Huss to the board on the same date, where she will serve on the Audit Committee. Huss brings extensive experience in medical devices and has previously held CEO positions at companies like Pagonia Medical and Qool Therapeutics. The company aims to enhance surgical procedures through innovative robotic technology.
Vicarious Surgical Inc. (RBOT) has announced a Demonstration Day for its Beta 2 surgical robot prototype, scheduled for December 6, 2022, at 11:00 a.m. ET in Waltham, MA. The event is exclusive, with limited in-person attendance by invitation only, but will be live-streamed for broader access. The company aims to enhance surgical efficiency and patient outcomes through innovative robotics technology.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) announced its participation in the Inaugural Gilmartin Group Emerging Growth Company Showcase, scheduled for August 31, 2022, at 11:30 am ET. The virtual event aims to highlight emerging growth companies. Vicarious Surgical focuses on enhancing surgical efficiency and patient outcomes through advanced robotic technology. A live webcast will be available through a provided link, with an archived version accessible on their investor website following the event.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) announced its Q2 2022 financial results, revealing a significant increase in operating expenses to $19.1 million, up from $6.6 million in Q2 2021. Adjusted net loss rose to $19.1 million, or $0.16 per share, compared to a loss of $6.6 million or $0.08 per share in the previous year. The company is advancing its Beta 2 system and partnering with UH Ventures and HCA Healthcare for surgical innovations. Cash burn rate for the quarter was $15.7 million. A conference call will be held today at 4:30 p.m. ET.